Climb Bio, Inc. Stock Analysis & AI Score
Climb Bio, Inc. (CLYM) has an ST Score of 60.2 (B), driven by its Financial Strength (A+) and held back by its Growth (D+). Analysts rate it Buy with a $26.55 price target (+123.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Climb Bio, Inc. (CLYM) has an ST Score of 60.2 (B), driven by its Financial Strength (A+) and held back by its Growth (D+). Analysts rate it Buy with a $26.55 price target (+123.3% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthD+
All factor grades
- Financial StrengthA+
- ForecastA
- ProfitabilityB+
- MomentumB+
- ValuationB-
- GrowthD+
- Piotroski2/9
Contact
CLYM stock: frequently asked questions
What is CLYM's ST Score?
Climb Bio, Inc. (CLYM) has an ST Score of 60.2 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CLYM a buy, hold, or sell?
Analysts rate CLYM a Buy, with a price target of $26.55 (+123.3% vs the current price). Our ST Score grades it B (60.2/100). The ST Score is a data-driven signal, not a recommendation.
What are CLYM's factor grades?
Valuation B-, Profitability B+, Financial Strength A+, Momentum B+, Growth D+, Forecast A.
What is CLYM's valuation grade?
Climb Bio, Inc. (CLYM) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CLYM's growth grade?
Climb Bio, Inc. (CLYM) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CLYM's profitability grade?
Climb Bio, Inc. (CLYM) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CLYM's financial strength grade?
Climb Bio, Inc. (CLYM) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CLYM?
The average analyst price target for Climb Bio, Inc. (CLYM) is $26.55 from 7 analysts, which is +123.3% versus the recent price of $11.89.
What is CLYM's Piotroski score?
Climb Bio, Inc. (CLYM) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.